R
Roser Torra
Researcher at Autonomous University of Barcelona
Publications - 178
Citations - 8220
Roser Torra is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Autosomal dominant polycystic kidney disease & Kidney disease. The author has an hindex of 43, co-authored 158 publications receiving 6738 citations. Previous affiliations of Roser Torra include University of Barcelona & Services Hospital.
Papers
More filters
Journal ArticleDOI
Unified Criteria for Ultrasonographic Diagnosis of ADPKD
York Pei,James Obaji,Annie Dupuis,Andrew D. Paterson,Riccardo Magistroni,Elizabeth Dicks,Patrick S. Parfrey,Benvon C. Cramer,Eliecer Coto,Roser Torra,José L. San Millán,Robert N Gibson,Martijn H. Breuning,Dorien J.M. Peters,David Ravine +14 more
TL;DR: A unified diagnostic criteria will be useful for testing individuals who are at risk for autosomal dominant polycystic kidney disease in the usual clinical setting in which molecular genotyping is seldom performed.
Journal ArticleDOI
Comparison of phenotypes of polycystic kidney disease types 1 and 2
Nick Hateboer,Marjan A. van Dijk,Nadja Bogdanova,Eliecer Coto,A K Saggar-Malik,José L. San Millán,Roser Torra,Martijn H. Breuning,David Ravine +8 more
TL;DR: Although PKD2 is clinically milder than PKD1, it has a deleterious impact on overall life expectancy and cannot be regarded as a benign disorder.
Journal ArticleDOI
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Arlene B. Chapman,Olivier Devuyst,Kai-Uwe Eckardt,Ron T. Gansevoort,Tess Harris,Shigeo Horie,Bertram L. Kasiske,Dwight Odland,York Pei,Ronald D. Perrone,Yves Pirson,Robert W. Schrier,Roser Torra,Vicente E. Torres,Terry Watnick,David C. Wheeler +15 more
TL;DR: This review summarized areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support that are summarized in this review.
Journal ArticleDOI
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Dominique P. Germain,Derralynn Hughes,Kathleen Nicholls,Daniel G. Bichet,Roberto Giugliani,William R. Wilcox,Claudio Feliciani,Suma P. Shankar,Fatih Süheyl Ezgü,Hernan Amartino,Drago Bratkovic,Ulla Feldt-Rasmussen,Khan Nedd,Usama A Sharaf El Din,Charles Marques Lourenço,Maryam Banikazemi,Joel Charrow,Majed Dasouki,David N. Finegold,P Giraldo,Ozlem Goker-Alpan,Nicola Longo,C. Ronald Scott,Roser Torra,Ahmad Tuffaha,Ana Jovanovic,Stephen Waldek,Seymour Packman,Elizabeth Ludington,Christopher Viereck,John Kirk,Julie Yu,Elfrida R. Benjamin,Franklin K. Johnson,David J. Lockhart,Nina Skuban,Jeff Castelli,Jay A. Barth,Carrolee Barlow,Raphael Schiffmann,Raphael Schiffmann +40 more
TL;DR: Among all randomly assigned patients with Fabry's disease (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migAlastat group and the placebo group.
Journal ArticleDOI
Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia
Christopher J. Ward,David Yuan,Tatyana V. Masyuk,Xiaofang Wang,Rachaneekorn Punyashthiti,Shelly Whelan,Robert L. Bacallao,Roser Torra,Nicholas F. LaRusso,Vicente E. Torres,Peter C. Harris +10 more
TL;DR: The localization of fibrocystin to cilia further strengthens that correlation and indicates that the primary defect in ARPKD may be linked to ciliary dysfunction.